CLINICAL NEWS
Dasatinib (Sprycel, Bristol-Myers Squibb) may increase the risk of PAH, according to an FDA Drug Safety Communication issued to healthcare professionals. » More
|
|
Middle-aged women with RLS may be at higher risk of developing high blood pressure, according to a study published online October 10 in Hypertension: Journal of the American Heart Association. » More |
ADVERTISEMENT
Resource Center: Oral Anticoagulation in Atrial Fibrillation
Atrial fibrillation afflicts more than 2.3 million persons in the United States and is expected to increase 2.5-fold by 2050. To find risk stratifying tools and articles on emerging oral anticoagulant therapies,
 click here. |
|
According to a recent study, $5.8 billion was spent in 1 year on the unnecessary prescription of brand-name statins. » More |
Survey
a) We follow the CMS-approved compendia. If a medication is listed, it is approved. We do not follow any pathway.
b) We follow the CMS-approved compendia, but a medication is only approved when it follows a pathway.
c) We follow internal guidelines. No pathway is required.
d) We follow internal guidelines, with only specific pathways.
Respond Here and see what your colleagues are using too.
Want to see the results of our last survey regarding Medco's acquisition by Express Scripts?
Click Here. |
Editor's Pick
THERAPY UPDATE
Tracking and preparing for the approval of generic products is 1 of the key components of proactive formulary management. Unfortunately, forecasting FDA approval of the first generic inhaled corticosteroid products is difficult. » Click here. |
|
FDA Commissioner Margaret A. Hamburg, MD, recently released a blueprint containing immediate steps that can be taken to drive biomedical innovation, while improving the health of Americans. » More |
|
The recent approval by FDA of an adult cancer therapy is 1 example of how children’s cancer research benefits patients of all ages. » More |
FDA ACTIONS
FDA has approved deferiprone (Ferriprox, ApoPharma) to treat patients with iron overload resulting from blood transfusions in patients with thalassemia. » More |
|
Vivus has resubmitted its NDA for Qnexa (phentermine/topiramate) to FDA. » More |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
